

Inoue Y, Aizaki H, Hara H, Matsuda M, Ando T, Shimoji T, Masaki T, Shoji I, Homma S, Matsuura Y, Miyamura T, Wakita T, Suzuki T.	Chaperonin TRiC/CCT participates in replication of hepatitis C virus genome via interaction with the viral NS5B protein.	Virology	410	38-47	2011
Iwasaki Y, Mori K, Ishii K, Maki N, Iijima S, Yoshida T, Okabayashi S, Katakai Y, Lee Y.J, Saito A, Funai H, Kimura N, Ageyama N, Yoshizaki S, Suzuki T, Yasutomi Y, Miyamura T, Kannagi M and Akari H	Long-term persistent GBV-B infection and development of a chronic and progressive hepatitis C-like disease in marmosets.	Front Microbiol.	2	240	2011
*Sa-Nguanmoo P, Tanaka Y, Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, Mizokami M, Poovorawan Y.	Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.	Virus Res.	158(1-2)	209-15	2011
Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M.	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial.	Hepatol Res.	41(6)	505-511	2011

*研究成果の別刷あり

平成 24 年度
雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Nishida N , Mawatari Y, Sageshima M, Tokunaga K .	Highly Parallel and Short-Acting Amplification with Locus-Specific Primers to Detect Single Nucleotide Polymorphisms by the DigiTag2 Assay.	PLoS One.	7(1)	e29967	2012
Sawai H, Nishida N , Mbarek H, Matsuda K , Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S , Watanabe M, Kurosaki M , Asahina Y, Izumi N, Honda M , Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K , Murawaki Y, Hiasa Y, Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y , Mizokami M , Tokunaga K .	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet	13	47	2012
* Nishida N , Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M , Asahina Y, Mochida S , Watanabe M, Tanaka E, Honda M , Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K , Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y , Tokunaga K , Mizokami M .	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.	PLoS One	7(6)	e39175	2012
*Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, Urabe Y, Mbarek H, Tokunaga K , Tanaka Y , Sugiyama M, Mizokami M , Muroyama R, Tateishi R, Omata M, Koike K , Tanikawa C, Kamatani N, Kubo M, Nakamura Y, Matsuda K .	Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma.	Plos One	7(9)	E44743	2012

Kawashima M, Ohashi J, <u>Nishida N, Tokunaga K</u>	Evolutionary analysis of classical HLA class I and II genes suggests that recent positive selection acted on DPB1*04:01 in Japanese population.	PLoS One	7(10)	e46806	2012
*Nakamura M, <u>Nishida N,</u> Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, Nakamura M, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Onji M, Kaneko S, <u>Honda M,</u> Yamagiwa S, Nakao K, Ichida T, Takikawa H, Seike M, Umemura T, Ueno Y, Sakisaka S, Kikuchi K, Ebinuma H, Yamashiki N, Tamura S, Sugawara Y, Mori A, Yagi S, Shirabe K, <u>Taketomi A,</u> Arai K, Monoe K, Ichikawa T, Taniai M, Miyake Y, Kumagi T, Abe M, Yoshizawa K, Joshita S, Shimoda S, Honda K, Takahashi H, Hirano K, Takeyama Y, Harada K, Migita K, Ito M, <u>Yatsushiro H,</u> Fukushima N, Ota H, Komatsu T, Saoshiro T, Ishida J, Kouno H, Kouno H, Yagura M, Kobayashi M, Muro T, Masaki N, Hirata K, Watanabe Y, Nakamura Y, Shimada M, Hirashima N, Komeda T, Sugi K, Koga M, Ario K, Takesaki E, Maehara Y, Uemoto S, Kokudo N, Tsubouchi H, <u>Mizokami M,</u> Nakanuma Y, <u>Tokunaga K,</u> Ishibashi H.	Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population.	Am J Hum Genet.	91(4)	721-728	2012
澤井裕美、 <u>徳永勝士</u>	ゲノム多様性と感染症	細胞	243(6)	555-560	2013
川嶋実苗、 <u>徳永勝士</u>	よくわかるゲノムワイド関連解析②: GWAS を読む - 質の管理	医学のあゆみ		555-560	2012

徳永勝士	よくわかるゲノムワイド 関連解析③: GWAS の今後の課題	医学のあ ゆみ		934-93 6	2012
新海登, 田中靖人, 杉山真也, 溝上雅史.	【B型肝炎の抗ウイルス療法 の進歩と耐性】 核酸アナ ログ耐性変異パターン 解析とその対策	消化器内 科	54(5)	582-58 5	2012
Anai Y, Ochi H, Watanabe S, Nakagawa S, Kawamura M, Gojobori T , Nishigaki K.	Infectious Endogenous Retroviruses in Cats and Emergence of Recombinant Viruses	J. of Virology	86 (16)	8634-4 4	2012
Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T .	Replication of hepatitis C virus genotype 3a in cultured cells.	Gastroente rology.	144(1)	56-58.e 7	2013
Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y , Mizokami M , Wakita T .	Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.	J Virol.	86(19)	10805- 20.	2012
Ando T, Imamura H, Suzuki R, Aizaki H, Watanabe T, Wakita T , Suzuki T.	Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA.	PLoS Pathog.	8(3)	e10025 61.	2012
Date T, Morikawa K, Tanaka Y , Tanaka-Kaneko K, Sata T, Mizokami M , Wakita T .	Replication and infectivity of a novel genotype 1b hepatitis C virus clone.	Microbiol Immunol.	56(5)	308-17.	2012
Bae SK, Yatsuhashi H , Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Abiru S, Komori A, Migita K, Nakamura M, Ito M, Miyakawa Y, Ishibashi H.	Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.	Med Sci Monit.	18(12)	CR 698-70 5	2012
*Toyama T, Ishida H, Ishibashi H, Yatsuhashi H , Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E.	Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B.	Hepatol Res.	42(12)	1168-7 4	2012

Migita K, Abiru S, Ohtani M, Jiuchi Y, Maeda Y, Bae SK, Bekki S, Hashimoto S, Yesmembetov K, Nagaoka S, Nakamura M, Komori A, Ichikawa T, Nakao K, <u>Yatsuhashi H</u> , Ishibashi H, Yasunami M.	HLA-DP gene polymorphisms and hepatitis B infection in the Japanese population.	Transl Res.	160(6)	443-4	2012
* <u>Matsumoto A</u> , Tanaka E, Suzuki Y, Kobayashi M, <u>Tanaka Y</u> , Shinkai N, Hige S, <u>Yatsuhashi H</u> , Nagaoka S, Chayama K, Tsuge M, <u>Yokosuka O</u> , Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.	Hepato Res.	42(2)	139-49	2012
<u>Matsumoto A</u> , Tanaka E, Morita S, Yoshizawa K, Umemura T, Joshita S	Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection.	J Gastroenterol.	47	1006-1013	2012
Wu S, Kanda T, Nakamoto S, Imazeki F, <u>Yokosuka O</u> .	Knockdown of receptor-interacting serine/threonine protein kinase-2 (RIPK2) affects EMT-associated gene expression in human hepatoma cells.	Anticancer Res.	32(9)	3775-83.	2012
*Wu S, Kanda T, Imazeki F, Nakamoto S, Tanaka T, Arai M, Roger T, Shirasawa H, Nomura F, <u>Yokosuka O</u> .	Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression.	J Infect Dis.	206(3)	415-20.	2012
Suzuki E, Chiba T, Zen Y, Miyagi S, Tada M, Kanai F, Imazeki F, Miyazaki M, Iwama A, <u>Yokosuka O</u> .	Aldehyde dehydrogenase 1 is associated with recurrence-free survival but not stem cell-like properties in hepatocellular carcinoma.	Hepato Res.	42(11)	1100-11.	2012
Yan J, Kanda T, Wu S, Imazeki F, <u>Yokosuka O</u> .	Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan.	Hepato Res.	42(10)	974-81.	2012

Hamaoka K, Nagoshi S, Sugawara K, Naiki K, Uchida Y, Inao M, Nakayama N, Fujiwara K, <u>Mochida S.</u>	SNPs in the Promoter Region of Osteopontin Gene as a Possible Host Factor for Sex Difference in Hepatocellular Carcinoma Development in Patients with HCV.	Hepatol Int	7(2)	683-692	2013
Sugawara K, Nakayama N, <u>Mochida S.</u>	Acute Liver failure in Japan: Definition, Classification, and Prediction of the Outcome.	J Gastroenterol	47	849-861	2012
*Nakayama N, Oketani M, Kawamura Y, Inao M, Nagoshi S, Fujiwara K, Tsubouchi H, <u>Mochida S.</u>	Algorithm to Determine the Outcome of Patients with Acute Liver Failure; a Data Mining Analysis Using Decision Trees.	J Gastroenterol	47	664-677	2012
Naiki T, Nakayama N, <u>Mochida S.</u> , Oketani M, Takikawa Y, Suzuki K, Tada S, Yano K, Ichida T, Moriwaki H, Tsubouchi H.	Novel Scoring System as a Useful Model to Predict the Outcome of Patients with Acute Liver Failure: Application to Indication Criteria for Liver Transplantation.	Hepatol Res	42	8-75	2012
Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, Umeshita K, Umemoto S, <u>Mochida S.</u> , Tsubouchi H, Kokudo N.	Outcomes after Living Liver Transplantation for Acute Liver Failure in Japan: Results of a Nationwide Survey.	Liver Transplant	18	1069-1077	2012.
Imai Y, Chikayama T, Makazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hanaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, <u>Mochida S.</u>	Usefulness of Miriplatin as an Anticancer Agent for Transcatheter Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma.	J Gastroenterol	47	179-186	2012
Hikita H, Enooku K, Satoh Y, Yoshida H, Nakagawa H, Masuzaki R, Tateishi R, Soroida Y, Sato M, Suzuki A, Gotoh H, Iwai T, Yokota H, <u>Koike K.</u> , Yatomi Y, Ikeda H.	Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon- α and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1	Hepatol Res	43(10)	1005-1022	2013
Gotoh H, Enooku K, Soroida Y, Sato M, Hikita H, Suzuki A, Iwai T, Yokota H, Yamazaki T, <u>Koike K.</u> , Yatomi Y, Ikeda H	Perihepatic lymph node enlargement observed at a general health examination: A cross-sectional study	Hepatol Res	43(8)	906-10	2013

Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, <u>Koike K</u>	The effectiveness of liraglutide in nonalcoholic Fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone	Scientific WorldJournal		496453	2012
Kurano M, Hara M, Tsuneyama K, Okamoto K, Iso-O N, Matsushima T, <u>Koike K</u> , Tsukamoto K	Modulation of lipid metabolism with the over-expression of NPC1L1 in mice liver	J Lipid Res	53(11)	2275-85	2012
Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang YJ, Maeda S, Yoshida H, Omata M, Asahara H, <u>Koike K</u>	MicroRNA-140 acts as a liver tumor suppressor by controlling NF- κ B activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression.	Hepatology	57	162-170	2013
Hikita H, Nakagawa H, Tateishi R, Masuzaki R, Enooku K, Yoshida H, Omata M, Soroida Y, Sato M, Gotoh H, Suzuki A, Iwai T, Yokota H, <u>Koike K</u> , Yatomi Y, Ikeda H	Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients	J Gastroenterol	48(3)	366-73	2013
Minami T, Kishikawa T, Sato M, Tateishi R, Yoshida H, <u>Koike K</u>	Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C	J Gastroenterol	48(2)	254-68	2013
Okushin K, Asaoka Y, Fukuda I, Fujiwara N, Minami T, Sato M, Mikami S, Uchino K, Enooku K, Kondo Y, Tateishi R, Goto T, Shiina S, Yoshida H, <u>Koike K</u>	IGF-II producing hepatocellular carcinoma treated with sorafenib: metabolic complications and a foresight to molecular targeting therapy to the IGF signal	Case Rep Gastroenterol	6(3)	784-789	2012
*Yanagimoto S, Yotsuyanagi H, Kikuchi Y, Tsukada K, Kato M, Takamatsu J, Hige S, Chayama K, Moriya K, <u>Koike K</u>	Chronic hepatitis B in patients coinfectd with human immunodeficiency virus in Japan: a retrospective multicenter analysis	J Infect Chemother	18(6)	883-890	2012
Ikeda H, Enooku K, Ohkawa R, <u>Koike K</u> , Yatomi Y	Plasma lysophosphatidic acid levels and hepatocellular carcinoma	Hepatology	57	417-418	2013
Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H, Omata M, <u>Koike K</u>	Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors	Liver Int	32(9)	1434-1442	2012

Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, <u>Koike K</u>	Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma	J Gastroenterol	47(10)	1152-1159	2012
Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, <u>Koike K</u>	Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients	J Gastroenterol	47(10)	1125-1133	2012
Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, <u>Koike K</u>	Silencing of microRNA-122 enhances interferon- α signaling in the liver through regulating SOCS3 promoter methylation	Sci Rep	2	637	2012
Nakagawa H, Isogawa A, Tateishi R, Tani M, Yoshida H, Yamakado M, <u>Koike K</u>	Serum gamma-glutamyltransferase level is associated with serum superoxide dismutase activity and metabolic syndrome in a Japanese population	J Gastroenterol	47(2)	187-194	2012
Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, <u>Koike K</u> , Yatomi Y, Ikeda H	Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence	J Hepatol	27(2)	330-336	2012
Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Kudo Y, Goto T, Yoshida H, <u>Koike K</u>	A miRNA machinery component DDX20 controls NF- κ B via microRNA-140 function	Biochem Biophys Res Commun	420(3)	564-569	2012
Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, <u>Koike K</u>	Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography	World J Gastroenterol	18(12)	1385-1390	2012
Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H, <u>Koike K</u>	Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation	Cancer Sci	103(4)	670-676	2012

Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, <u>Koike K</u>	Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma	J Gastroenterol	47(4)	47(4)	2012
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, <u>Koike K</u>	Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors	Am J Gastroenterol	107(4)	569-577	2012
Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, <u>Koike K</u>	Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times	J Gastroenterol	47(1)	71-78	2012
*Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, <u>Sakamoto M</u> , Nakashima O, Matsui O, Matsuyama Y.	Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey.	J Hepatol.	58(4)	724-9	2013
Fukuma M, Tanese K, Effendi K, Yamazaki K, Masugi Y, Suda M, <u>Sakamoto M</u> .	Leucine-rich repeat-containing G protein-coupled receptor 5 regulates epithelial cell phenotype and survival of hepatocellular carcinoma cells.	Exp Cell Res.	319(3)	113-21	2013
*Effendi K, Yamazaki K, Mori T, Masugi Y, Makino S, <u>Sakamoto M</u> .	Involvement of hepatocellular carcinoma biomarker, cyclase-associated protein 2 in zebrafish body development and cancer progression.	Exp Cell Res.	319(1)	35-44	2013
Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Kakisaka T, Tsuruga Y, Todo S, <u>Taketomi A</u> .	Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma.	World J Surg Oncol	14(10)	107	2012
<u>Hino K</u> , Nishina S, Hara Y	Iron metabolic disorder in chronic hepatitis C: insights from recent evidence	Clin J Gastroenterol	5	251-6	2012

Matsui T, Motoki Y, Inomoto T, Miura D, Kato Y, Suenaga H, Hino K , Nojima J.	Temperature-related effects of adenosine triphosphatase-activated microglia on pro-inflammatory factors	Neurocrit Care	17	293-300	2012
Nakagawa M, Sakamoto N , Watanabe T, Nishimura-Sakurai Y, Onozuka Y, Azuma S, Kakinuma S, Nitta S, Kiyohashi K, Kusano-Kitazume A, Murakawa M, Yoshino K, Itsui Y, Tanaka Y , Mizokami M , Watanabe M, Ochanomizu Liver Conference Study Group	Association of ITPA gene variant and serum ribavirin concentration with blood cells decline in pegylated interferon-alfa plus ribavirin therapy for chronic hepatitis C.	Hepatol Int	7(1)	153-161	2013
Kohjima M, Enjoji M, Yoshimoto T, Yada R, Fujino T, Aoyagi Y, Fukushima N, Fukuizumi K, Harada N, Yada M, Kato M, Kotoh K, Nakashima M, Sakamoto N , Tanaka Y , Nakamura M	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.	J Med Virol	85(2)	250-260	2013
Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N , Asaka M	Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.	J Gastroenterol	47(11)	1228-1237	2012
Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M , Enomoto N, Nitta S, Sakamoto N , Izumi N	Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response	Hepatology	55(1)	20-29	2012
Ueda T, Honda M , Horimoto K, Aburatani S, Saito S, Yamashita T, Sakai S, Nakamura M, Takatori H, Sunagozaka H, Kaneko S.	Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling.	Genomics.	101(4)	238-48	2013
Sakai Y, Tatsumi I, Higashimoto M, Seki A, Nasti A, Yoshida K, Kawaguchi K, Wada T, Honda M , Komura T, Kaneko S.	Association of changes in the gene expression profile of blood cells with the local tumor inflammatory response in a murine tumor model.	Biochem Biophys Res Commun.	428(1)	36-43	2012

Mizukoshi E, Fushimi K, Arai K, Yamashita T, Honda M , Kaneko S.	Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma.	Liver Int.	32(10)	1516-26	2012
Okada H, Honda M , Campbell JS, Sakai Y, Yamashita T, Takebuchi Y, Hada K, Shirasaki T, Takabatake R, Nakamura M, Sunagozaka H, Tanaka T, Fausto N, Kaneko S.	Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development.	Cancer Res.	72(17)	4459-71	2012
Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M , Nakamoto Y, Onchi M, Shiota G, Yokosuka O , Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y.	Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.	Hepatol Res.	42(6)	523-542	2012
Takeshita Y, Takamura T, Kita Y, Ando H, Ueda T, Kato K, Misu H, Sunagozaka H, Sakai Y, Yamashita T, Mizukoshi E, Honda M , Kaneko S.	Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance: implications for type 2 diabetes.	Metabolism.	61(10)	1388-94	2012
*He D, Liu ZP, Honda M , Kaneko S, Chen L.	Coexpression network analysis in chronic hepatitis B and C hepatic lesions reveals distinct patterns of disease progression to hepatocellular carcinoma.	J Mol Cell Biol.	4(3)	140-52	2012
Mizuno H, Honda M , Shirasaki T, Yamashita T, Yamashita T, Mizukoshi E, Kaneko S.	Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.	Liver Int.	32(7)	1146-55	2012
Sato Y, Ren XS, Harada K, Sasaki M, Morikawa H, Shiomi S, Honda M , Kaneko S, Nakanuma Y.	Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.	Clin Exp Immunol.	167(3)	532-42	2012

Nakamura S, Kawai K, Takeshita Y, Honda M , Takamura T, Kaneko S, Matoba R, Matsubara K.	Identification of blood biomarkers of aging by transcript profiling of whole blood.	Biochem Biophys Res Commun.	418(2)	313-8	2012
Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M , Kusumoto Y, Tsutsumi T, Sakata K.	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.	Invest New Drugs.	30(5)	2015-25	2012
Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, Tanaka Y , Zhang X, Narimatsu H.	Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels.	Clin Chim Acta.	413(21-22)	1796-9	2012
Michikawa T, Inoue M, Sawada N, Iwasaki M, Tanaka Y , Shimazu T, Sasazuki S, Yamaji T, Mizokami M , Tsugane S; Japan Public Health Center-based Prospective Study Group.	Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II.	Prev Med.	55(2)	137-43	2012
Zhou B, Wang Z, Yang J, Sun J, Li H, Tanaka Y , Mizokami M , Hou J.	Novel evidence of HBV recombination in family cluster infections in western China.	PLoS One.	7(6)	e38241	2012
*Kondo Y, Ueno Y, Ninomiya M, Tamai K, Tanaka Y , Inoue J, Kakazu E, Kobayashi K, Kimura O, Miura M, Yamamoto T, Kobayashi T, Igarashi T, Shimosegawa T.	Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.	J Gastroenterol.	47(12)	1323-35	2012
Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takachi R, Tanaka Y , Mizokami M , Tsugane S; Japan Public Health Center-Based Prospective Study Group	Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma.	Gastroenterology.	142(7)	1468-75	2012

Ragheb M, Elkady A, <u>Tanaka Y</u> , Murakami S, Attia FM, Hassan AA, Hassan MF, Shedid MM, Abdel Reheem HB, Khan A, <u>Mizokami M</u> .	Multiple intra-familial transmission patterns of hepatitis B virus genotype D in north-eastern Egypt.	J Med Virol.	84(4)	587-95	2012
Kuno A, Ikehara Y, <u>Tanaka Y</u> , Ito K, Matsuda A, Sekiya S, Hige S, <u>Sakamoto M</u> , Kage M, <u>Mizokami M</u> , Narimatsu H.	A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.	Sci Rep.	3	1065	2013
Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, <u>Tanaka Y</u> , Chu CK.	2'-Fluoro-6'-methylene-carbo cyclic adenosine phosphoramidate (FMCAP) prodrug: In vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.	Bioorg Med Chem Lett.	23(2)	503-6	2013
Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, <u>Tanaka Y</u> , <u>Mizokami M</u> .	Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey.	Microbiol Immunol.	57(2)	122-9.	2013
Watanabe T, <u>Tanaka Y</u> .	Reactivation of hepatitis viruses following immunomodulation systemic chemotherapy.	Hepatol Res.	43(2)	113-21	2012
Sakamoto T, <u>Tanaka Y</u> , Watanabe T, Iijima S, Kani S, Sugiyama M, Murakami S, Matsuura K, Kusakabe A, Shinkai N, Fuminaka S, <u>Mizokami M</u> .	Mechanism of the dependence of hepatitis B virus genotype G on co-infection with other genotypes for viral replication.	J Viral Hepat.	20(4)	e27-36	2013

平成 25 年度
書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
徳永勝士	多因子疾患に関する大規模ゲノム解析研究の最前線		MEDICAL TECHNOLOGY 3	医歯薬出版株式会社		2014	42(3): 272-276
長岡進矢, 八橋 弘 .	インターフェロン治療, -III. 治療編, 2. 抗ウイルス薬による治療-	田中榮司 他	HEPATOLOGY PRACTICE 1 B 型肝炎の診療を極める -基本から最前線まで	文光堂	東京	2013	97-103
八橋 弘 .	I. HBV とその感染症の基礎, 4. HBV 感染の診断法	持田智	de novo B 型肝炎 -HBV 再活性化予防のための基礎知識-	医薬ジャーナル社	大阪	2013	55-67
八橋 弘 .	PegIFN と HBs 抗原量	溝上雅史	別冊・医学のあゆみ B 型肝炎 -最新治療コンセンサス	医歯薬出版株式会社	東京	2013	63-68

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Nishida N, Tokunaga K , and Mizokami M:	Genome-wide association study reveals host genetic factors for liver diseases.	J. Clin. Translat. Hepatol.	in press		2014
*Tokunaga K	Lessons from genome-wide search for disease-related genes with special reference to HLA-disease associations.	Genes	5	e84-96	2014
*Nishida N , Sawai H; Kashiwase K, Minami M, Sugiyama M, Seto WK, Yuen MF, Posuwan N, Poovorawan Y, Ahn SH, Han KH, Matsuura K, Tanaka Y , Kurosaki M , Asahina Y, Izumi N, Kang JH, Hige S, Ide T, Yamamoto K, Sakaida I, Murawaki Y, Itoh Y, Tamori A, Orito E, Hiasa Y, Honda M , Kaneko S, Mita E, Suzuki K, Hino K , Tanaka E, Mochida S ,	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia.	PLoS One	in press		2014

Watanabe M, Eguchi Y, Murata K, Korenaga M, Mawatari Y, Ohashi J, Kawashima M, <u>Tokunaga K, Mizokami M.</u>					
<u>Kusumoto S, Tanaka Y, Mizokami M,</u> Ueda R.	Strategy for preventing hepatitis B reactivation in patients with resolved HBV infection following rituximab-containing chemotherapy	Hepatology			2013
<u>Kusumoto S, Tanaka Y, Mizokami M,</u> Ueda R	Is Antiviral Prophylaxis Necessary to Prevent Hepatitis B Virus (HBV) Reactivation in Patients With HBV-Resolved Infection Receiving Rituximab-Containing Chemotherapy?	J Clin Oncol.	31(35)	4480	2013
Trinks J, Sugiyama M, <u>Tanaka Y,</u> Kurbanov F, Benetucci J, Giménez E, Weissenbacher MC, <u>Mizokami M,</u> Oubiña JR	In vitro replication competence of a hepatitis B genotype D/A recombinant virus: dissimilar biological behaviour regarding its parental genotypes	J Gen Virol	94	2724-8	2013
*Ito K, Yotsuyanagi H, <u>Yatsuhashi H,</u> Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, <u>Tanaka Y,</u> Sugiyama M, Murata K, Masaki N, <u>Mizokami M</u>	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults	Hepatology	59(1)	89-97	2014
Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, <u>Mizokami M,</u> Miyakawa Y, <u>Koike K</u>	High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B	Clin Infect Dis	57(7)	935-42	2013
Nakano N, <u>Kusumoto S,</u> <u>Tanaka Y,</u> Ishida T, Takeuchi S, Takatsuka Y, Akinaga S, <u>Mizokami M,</u> Ueda R, Utsunomiya A	Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab	Hepatol Res			2013

Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y , Kanai Y, Kusuhara H, Mizokami M , Wakita T .	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter NTCP.	Hepatology.	doi: 10.1002/hep.26982.	[Epub ahead of print]	2013
Nakagawa, S., Bai, H., Sakurai, T., Nakaya, Y., Konno, T., Miyazawa, T., Gojobori, T. , Imakawa, K.	Dynamic Evolution of Endogenous Retrovirus-Derived Genes Expressed in Bovine Conceptuses during the Period of Placentation.	Genome Biol Evol	5(2)	296-306	2013
Takeda, J., Yamasaki, C., Murakami, K., Nagai, Y., Sera, M., Hara, Y., Obi, N., Habara, T., Gojobori, T. , Imanishi, T.	H-InvDB in 2013: an omics study platform for human functional gene and transcript discovery.	NAR	41(D1)	D915-9	2013
Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T .	Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.	Biochem Biophys Res Commun.	443(3)	808-13	2014
Okamoto Y, Shinjo K, Shimizu Y, Sano T, Yamao K, Gao W, Fujii M, Osada H, Sekido Y, Murakami S, Tanaka Y , Joh T, Sato S, Takahashi S, Wakita T , Zhu J, Issa JP, Kondo Y.	Hepatitis virus infection affects DNA methylation in mice with humanized livers.	Gastroenterology.	146(2)	562-72.	2014
*Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, Suzuki R, Li J, Tong S, Tanaka Y , Murata K, Aizaki H, Wakita T .	Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase AID.	J Biol Chem.	288(44)	31715-27	2013
八橋 弘	ウイルス肝炎と肝癌の撲滅を目指した実地診療のすすめかた, B型肝炎の自然経過と治療の進歩—実地医家はどのように対処すればよいのか—	Medical Practice	30(2)	186-193	2013

*Morita S, <u>Matsumoto A</u> , Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Yoshizawa K, Tanaka E.	Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B.	Hepatol Res	impres s			2013
Kanda T, Jiang X, Nakamoto S, Nakamura M, Miyamura T, Wu S, <u>Yokosuka O</u> .	Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells.	Cytokine	64(2)	577-83		2013
Jiang X, Kanda T, Tanaka T, Wu S, Nakamoto S, Imazeki F, <u>Yokosuka O</u> .	Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines.	Immunol Lett	152(1)	8-15		2013
Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, Ono SK, Takahashi-Nakaguchi A, Gono T, <u>Yokosuka O</u> .	Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.	PLoS One	8(9)	e73615		2013
*Miyachi T, Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Kato K, Arai M, Mikami S, Sugiura N, Kimura M, Goto N, Imazeki F, <u>Yokosuka O</u> .	Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients.	Int J Med Sci	10(6)	647-52		2013
Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F, Nomura F, <u>Yokosuka O</u> .	Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine.	Int J Med Sci	10(5)	567-74		2013
Harigai M, <u>Mochida S</u> , Mimura T, <u>Koike T</u> , Miyasaka N.	The proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.	Mod Rheumatol	24	1-7		2014
Ge X, Leung TM, Arriazu E, Lu Y, Urtasun R, Christensen B, Fiel MI, <u>Mochida S</u> , Sørensen ES, Nieto N.	Osteopontin binding to lipopolysaccharide lower tumor necrosis factor- α and prevents early alcohol-induced liver injury in mice.	Hepatology		doi: 10.100 2/hep.2 6931.		2013 Nov 9 [Epub ahead of pront].

*Uchida Y, Kouyama J, Naiki K, Sugawara K, Inao M, Nakayama N, <u>Mochida S.</u>	Novel hepatitis B virus strain developing due to recombination between genotypes H and B strains isolated from a Japanese patient	Hepatol Res		Doi: 10.1111/hepr.12238	2013 Sep 10.
Hamaoka K, Nagoshi S, Sugawara K, Naiki K, Uchida Y, Inao M, Nakayama N, Fujiwara K, <u>Mochida S.</u>	SNPs in the promoter region of osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV.	Hepatol Int	7	683-692	2013
Oketani M, Ide A, Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, Ichida T, <u>Mochida S,</u> Ohnishi S, Tsubouchi H	Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009.	Hepatol Res	43	97-105	2013
<u>Mochida S,</u> Takikawa Y, Nakatama N, Oektani M, Maiki T, Yamagishi Y, Fujiwara K, Ichida K, Tsubouchi H.	Classification of the etiologies of acute liver failure in Japan: A report by the Intractable Hepato-Biliary Diseases Study Group of Japan.	Hepatol Res	in press		2014
Nakagawa H, Hikiba Y, Hirata Y, Font-Burgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A, Kinoshita H, Sakitani K, Nishikawa Y, Hirano K, Ikenoue T, Ijichi H, Dhar D, Shibata W, Akanuma M, <u>Koike K,</u> Karin M, Maeda S.	Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis.	Proc Natl Acad Sci U S A			[Epub ahead of print]
Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, <u>Koike K.</u>	The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.	J Gastroenterol			[Epub ahead of print]
Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, Tateishi R, Yoshida H, Shinzawa S, Moriya K, Ohtomo N, Nishikawa T, Inoue Y, Tomiya T, Kojima S, Matsuura T, <u>Koike K,</u> Yatomi Y, Ikeda H.	High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential.	Int J Cancer			[Epub ahead of print]

Shibata C, Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A, Yoshida H, <u>Koike K.</u>	Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression.	Biochem Biophys Res Commun			[Epub ahead of print]
Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, Fushimi K, <u>Koike K.</u>	Acute liver disease in Japan: a nationwide analysis of the Japanese Diagnosis Procedure Combination database.	J Gastroenterol			[Epub ahead of print]
Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, <u>Mizokami M,</u> Miyakawa Y, <u>Koike K.</u>	High levels of HBV after the onset lead to chronic infection in patients with acute hepatitis B.	Clin Infect Dis	57(7)	935-942	2013
Mikoshiha N, Miyashita M, Sakai T, Tateishi R, <u>Koike K.</u>	Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life.	Psychooncology			[Epub ahead of print]
Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, <u>Koike K.</u>	CT with hepatic arteriography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial.	Am J Gastroenterol	108	1305-1313	2013
Inoue Y, Tomiya T, Nishikawa T, Ohtomo N, Tanoue Y, Ikeda H, <u>Koike K.</u>	Induction of p53-Dependent p21 Limits Proliferative Activity of Rat Hepatocytes in the Presence of Hepatocyte Growth Factor.	PLoS One	8(11)	e78346	2013
He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapur S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, <u>Koike K,</u> Karin M.	Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.	Cell	155(2)	384-396	2013
*Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Takata A, Shibata C, Kondo Y, Akanuma M, Yoshida H, <u>Koike K.</u>	Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs.	Sci Rep	3	2739	2013

Liu Y, Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Koike K , Hirota K, Fukumoto M, Fujita J.	Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1.	Biochem Biophys Res Commun	432(1)	22-27	2013
Ohno M, Shibata C, Kishikawa T, Yoshikawa T, Takata A, Kojima K, Akanuma M, Kang YJ, Yoshida H, Otsuka M, Koike K .	The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice.	Sci Rep	3	2553	2013
Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K , Hayashi N, Kumada H.	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B.	Hepatology Res	43(6)	596-604	2013
Tateishi R, Shiina S, Akahane M, Sato J, Kondo Y, Masuzaki R, Nakagawa H, Asaoka Y, Goto T, Otomo K, Omata M, Yoshida H, Koike K .	Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma.	PLoS One	8(4)	e59040	2013
Ikeda H, Enooku K, Ohkawa R, Koike K , Yatomi Y.	Plasma lysophosphatidic acid levels and hepatocellular carcinoma.	Hepatology	57	417-418	2013
Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang YJ, Maeda S, Yoshida H, Omata M, Asahara H, Koike K .	MiRNA-140 acts as a liver tumor suppressor by controlling NF- κ B activity via directly targeting Dnmt1 expression.	Hepatology	57	162-170	2013
*Fukuma M, Tanese K, Effendi K, Yamazaki K, Masugi Y, Suda M, Sakamoto M .	Leucine-rich repeat-containing G protein-coupled receptor 5 regulates epithelial cell phenotype and survival of hepatocellular carcinoma cells.	Exp Cell Res.	319	113-121	2013
Effendi K, Yamazaki K, Mori T, Masugi Y, Makino S, Sakamoto M .	Involvement of hepatocellular carcinoma biomarker, cyclase-associated protein 2 in zebrafish body development and cancer progression.	Exp Cell Res.	319	35-44	2013